Search results
‘I Tried Out For A Reality Dating Show But Got Ghosted After My Photos Showed My Psoriasis’
Women's Health via Yahoo News· 4 days agoMichelle Lee had an itchy skin rash from plaque psoriasis for months, but doctors mistook it for an...
Does the Anti-Inflammatory Diet for Psoriasis Help Manage Symptoms?
Verywell Health via Yahoo News· 1 day agoInflammation is one of the underlying causes of psoriasis, and research shows that an...
FDA Approves Second Ustekinumab Biosimilar
Medscape· 7 days agoThe biosimilar is expected to be marketed in the United States on or after February 21, 2025.
FDA Approval of Alvotech/Teva Ustekinumab Biosimilar | JD Supra
JD Supra· 11 hours agoOn April 16, Alvotech and Teva announced the FDA approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Johnson and Johnson’s STELERA® (ustekinumab). The product was approved as a subcutaneous ...
Salicylic acid for psoriasis: Benefits, risks, and uses
Medical News Today· 7 days agoSalicylic acid may reduce both the appearance and symptoms of psoriasis. It can exfoliate the skin...
Skin Cancer and Rash: When Do Symptoms Suggest Cancer?
Verywell Health via Yahoo News· 6 days agoThis rash appears as a scaly, itchy rash that may eventually cover the entire body. Symptoms of...
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment
Morningstar· 7 days agoThe treatment is for patients with moderate to severe plaque psoriasis, adults with active psoriatic arthritis and pediatric patients six years and older ...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...
Morningstar· 7 days agoFood and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque ...
Stelara biosimilar from Alvotech, Teva approved by FDA
BioPharma Dive via Yahoo Finance· 6 days agoThe FDA cleared Selarsdi for treatment of moderate to severe plaque psoriasis and active psoriatic...
VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Ventyx...
Morningstar· 2 days agoDo you, or did you, own shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX)? Did you purchase your shares pursuant and/or traceable to the Company’s October 21, 2021 IPO, or between October 21 ...